Last reviewed · How we verify
Primatene Mist
Epinephrine acts as a beta-2 adrenergic agonist to relax bronchial smooth muscle and relieve acute bronchospasm.
Epinephrine acts as a beta-2 adrenergic agonist to relax bronchial smooth muscle and relieve acute bronchospasm. Used for Acute bronchospasm and asthma attacks (over-the-counter emergency relief).
At a glance
| Generic name | Primatene Mist |
|---|---|
| Sponsor | Amphastar Pharmaceuticals, Inc. |
| Drug class | Beta-2 adrenergic agonist (short-acting) |
| Target | Beta-2 adrenergic receptor |
| Modality | Small molecule |
| Therapeutic area | Respiratory |
| Phase | FDA-approved |
Mechanism of action
Primatene Mist delivers epinephrine via inhalation, which binds to beta-2 adrenergic receptors on airway smooth muscle, causing rapid bronchodilation. This reverses acute airway constriction and restores airflow in patients experiencing asthma attacks or acute bronchospasm. The effect is rapid but short-lived, typically lasting 1-4 hours.
Approved indications
- Acute bronchospasm and asthma attacks (over-the-counter emergency relief)
Common side effects
- Tremor
- Nervousness or anxiety
- Headache
- Palpitations
- Tachycardia
Key clinical trials
- A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001) (PHASE3)
- Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia (PHASE2)
- Testing Trametinib as a Potential Targeted Treatment in Cancers With GNAQ or GNA11 Genetic Changes (MATCH-Subprotocol S2) (PHASE2)
- Efficacy and Safety of Fully Resorbable Sinus Drug-eluting Stents in Patients With Eosinophilic Chronic Rhinosinusitis With Nasal Polyps After Surgery: A Prospective, Randomized Controlled Trial (NA)
- Clinical and Molecular Characteristics of Primary Aldosteronism in Blacks
- Treatment Strategies for IgG4-RD Patients With Superficial Organ Involvement (NA)
- Sleep Loss and Circadian Misalignment - Mechanisms of Insulin Resistance (PHASE4)
- Parenting and CAH - 21-hydroxylase Deficiency
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |